RESEARCH LETTER

SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension

肝硬化合并糖尿病患者的SGLT2抑制剂:一项三级中心队列研究和对门静脉高压症潜在治疗靶点的认识

Corresponding Author

Saad Saffo

[email protected]

orcid.org/0000-0001-5375-3100

Department of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, Connecticut, USA

Correspondence

Saad Saffo, Department of Internal Medicine, Section of Digestive Diseases, 333 Cedar Street, 1080 LMP, New Haven, CT 06520-8019, USA.

Email: [email protected]

Search for more papers by this author

Guadalupe Garcia-Tsao,

Guadalupe Garcia-Tsao

Department of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, Connecticut, USA

Department of Internal Medicine, Section of Digestive Diseases, VA Connecticut Healthcare System, West Haven, Connecticut, USA

Search for more papers by this author

Tamar Taddei,

Tamar Taddei

Department of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, Connecticut, USA

Department of Internal Medicine, Section of Digestive Diseases, VA Connecticut Healthcare System, West Haven, Connecticut, USA

Search for more papers by this author

Saad Saffo,

Corresponding Author

Saad Saffo

[email protected]

orcid.org/0000-0001-5375-3100

Department of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, Connecticut, USA

Correspondence

Saad Saffo, Department of Internal Medicine, Section of Digestive Diseases, 333 Cedar Street, 1080 LMP, New Haven, CT 06520-8019, USA.

Email: [email protected]

Search for more papers by this author

Guadalupe Garcia-Tsao,

Guadalupe Garcia-Tsao

Department of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, Connecticut, USA

Department of Internal Medicine, Section of Digestive Diseases, VA Connecticut Healthcare System, West Haven, Connecticut, USA

Search for more papers by this author

Tamar Taddei,

Tamar Taddei

Department of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, Connecticut, USA

Department of Internal Medicine, Section of Digestive Diseases, VA Connecticut Healthcare System, West Haven, Connecticut, USA

Search for more papers by this author

First published: 19 November 2020

https://doi.org/10.1111/1753-0407.13136

Citations: 8

Share a link

Email
Wechat
Bluesky

Graphical Abstract

Highlights

Sodium glucose cotransporter 2 (SGLT2) inhibitors have favorable pleiotropic effects in patients with diabetes mellitus and cardiovascular or renal disease.
The benefits of SGLT2 inhibitors may extend to portal hypertension, but they have not been formally evaluated in patients with cirrhosis.
Our study is the first to provide clinical data for SGLT2 inhibitors in a cohort of patients with cirrhosis, and our findings support ongoing evaluation in the form of a clinical trial.

REFERENCES

1Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373: 2117-2128.
10.1056/NEJMoa1504720
CAS PubMed Web of Science® Google Scholar
2Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. Eur Heart J. 2016; 37: 1526-1534.
10.1093/eurheartj/ehv728
CAS PubMed Web of Science® Google Scholar
3Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019; 380: 2295-2306.
10.1056/NEJMoa1811744
CAS PubMed Web of Science® Google Scholar
4Scheen AJ. Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: a common comorbidity associated with severe complications. Diabetes Metab. 2019; 45: 213-223.
10.1016/j.diabet.2019.01.008
CAS PubMed Web of Science® Google Scholar
5Kuchay MS, Krishan S, Mishra SK, et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial). Diabetes Care. 2018; 41: 1801-1808.
10.2337/dc18-0165
CAS PubMed Web of Science® Google Scholar
6Akuta N, Watanabe C, Kawamura Y, et al. Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: preliminary prospective study based on serial liver biopsies. Hepatol Commun. 2017; 1: 46-52.
10.1002/hep4.1019
CAS PubMed Web of Science® Google Scholar
7Saffo S, Taddei T. SGLT2 inhibitors and cirrhosis: a unique perspective on the co-management of diabetes mellitus and ascites. Clin Liver Dis (Hoboken). 2018; 11: 141-144.
10.1002/cld.714
PubMed Google Scholar
8Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care. 2016; 39: 1115-1122.
10.2337/dc16-0542
CAS PubMed Web of Science® Google Scholar
9Wan N, Rahman A, Hitomi H, Nishiyama A. The effects of sodium-glucose cotransporter 2 inhibitors on sympathetic nervous activity. Front Endocrinol (Lausanne). 2018; 9: 421.
10.3389/fendo.2018.00421
PubMed Web of Science® Google Scholar
10Fleming KM, Aithal GP, Card TR, West J. The rate of decompensation and clinical progression of disease in people with cirrhosis: a cohort study. Aliment Pharmacol Ther. 2010; 32: 1343-1350.
10.1111/j.1365-2036.2010.04473.x
CAS PubMed Web of Science® Google Scholar
11Samonakis DN, Koulentaki M, Coucoutsi C, et al. Clinical outcomes of compensated and decompensated cirrhosis: a long term study. World J Hepatol. 2014; 6: 504-512.
10.4254/wjh.v6.i7.504
PubMed Google Scholar
12DʼAmico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006; 44: 217-231.
10.1016/j.jhep.2005.10.013
PubMed Web of Science® Google Scholar
13Griffin M, Riello R, Rao VS, et al. Sodium glucose cotransporter 2 inhibitors as diuretic adjuvants in acute decompensated heart failure: a case series. ESC Heart Fail. 2020; 7(4): 1966-1971.
10.1002/ehf2.12759
PubMed Web of Science® Google Scholar
14Griffin M, Rao VS, Ivey-Miranda J, et al. Empagliflozin in heart failure: diuretic and cardio-renal effects. Circulation. 2020; 142: 1028-1039. https://doi.org/10.1161/CIRCULATIONAHA.120.045691.
10.1161/CIRCULATIONAHA.120.045691
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume13, Issue3

March 2021

Pages 265-269

SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension

肝硬化合并糖尿病患者的SGLT2抑制剂:一项三级中心队列研究和对门静脉高压症潜在治疗靶点的认识

Graphical Abstract

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension

肝硬化合并糖尿病患者的SGLT2抑制剂:一项三级中心队列研究和对门静脉高压症潜在治疗靶点的认识

Graphical Abstract

REFERENCES

Citing Literature

References

Related

Information